Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Dendritic cells (DCs) are crucial for T cell activation and cancer immunity.
• Defects in DC and T cell function are observed in renal cell carcinoma (RCC).
• Myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) have distinct roles in cancer immunity.

Purpose of the Study:

• Investigate frequencies and activation states of mDC and pDC subsets in RCC patients.
• Compare DC subsets in peripheral blood, tumor tissues, and lymph nodes of RCC patients versus healthy donors.
• Assess the potential of ex vivo generated mDCs for RCC immunotherapy.

Main Methods:

• Flow cytometry and immunohistochemistry were used to analyze DC subsets.
• Monoclonal antibodies (mAbs) BDCA-2, BDCA-4, BDCA-1, and BDCA-3 identified pDCs and mDC subsets (mDC1, mDC2).
• Immature (DC-LAMP(-)) and mature (CD83(+)) DC phenotypes were assessed.

Main Results:

• Both mDC and pDC subsets were significantly reduced in the peripheral blood of RCC patients.
• mDCs and pDCs infiltrated RCC tumor tissues but displayed an immature phenotype.
• Immature DCs in tumors were unable to mature or migrate to lymph nodes.
• Ex vivo generated mDCs from RCC patients stimulated potent anti-tumor cytotoxic T lymphocytes (CTLs) in vitro.

Conclusions:

• RCC is associated with reduced peripheral blood DCs and immature tumor-infiltrating DCs.
• Immature DCs in RCC tumors may impair anti-tumor immune responses.
• Ex vivo generated mDCs hold promise for DC-based vaccines in RCC patients with compromised immune systems.